Slide 1: Teleflex Incorporated Second Quarter 2010 Conference Call
1 TELEFLEX INCORPORATED SECOND QUARTER 2010 CONFERENCE CALL Exhibit 99.1
Slide 2: Forward-Looking Statements/Additional Notes
2 2 2 Forward-Looking Statements/Additional Notes This presentation and our discussion contain forward-looking information and statements including, but not limited to, expected benefits from elimination of certain management positions; upcoming 2010 Medical Segment product launches; forecasted 2010
Slide 3: Conference Call Logistics
3 Conference Call Logistics The release, accompanying slides, and replay webcast available online at www.teleflex.com (click on "Investors") Telephone replay available by dialing 888-286-8010 or for international calls, 617- 801-6888, pass code number 80213544
Slide 4: Quarter & Year Highlights
QUARTER & YEAR HIGHLIGH Teleflex:
Slide 5: June Quarter-to-Date Highlights
5 June Quarter-to-Date Highlights Revenue up 5% compared to prior year quarter; up 7% constant currency On a constant currency basis: Medical revenue growth of 2%; up 3% excluding impact of IV tubing recall Aerospace revenue growth of 32% Commercial revenue growth of 25% Adjusted operating margins o
Slide 6: June Quarter-to-Date Highlights: FDA Progress and Transformation
6 June Quarter-to-Date Highlights Continue to make progress with FDA FDA has begun the approval process of CFG requests Continued Company's transformation Announced organizational and leadership changes associated with continued transition to medical technology business Divested Rigging Services for
Slide 7: June Year-to-Date Highlights
7 June Year-to-Date Highlights Revenue up 3% compared to first six months of 2009; up 3% constant currency On a constant currency basis: Medical revenue growth of 1%; up 2% excluding impact of IV tubing recall Aerospace revenue growth of 4% Commercial revenue growth of 21% Adjusted gross margins of
Slide 8: Second Quarter Segment Revenue Review
8 SECOND QUARTER SEGMENT REVENUE REVIEW
Slide 9: Medical
9 Medical Critical Care Surgical Care Cardiac Care OEM 0.66 0.18 0.05 0.11 North America EMEA Asia / Latin America 0.53 0.34 0.13 Q2'10 Revenue Sales = $358.4 million, up 2% constant currency Q2'10 Constant Currency Revenue Results Critical Care: $233.7 million, up 2% Surgical Care: $66.2 million, d
Slide 10: Critical Care
10 Critical Care Vascular Access Respiratory Urology Anesthesia 0.44 0.19 0.15 0.22 North America EMEA Asia / Latin America 0.5 0.36 0.14 Q2'10 Revenue Vascular decline of 1%; excluding IV tubing recall, vascular up 2% Anesthesia sales up low-single digits Respiratory sales increase upper-single dig
Slide 11: Surgical Care
11 Surgical Care North America EMEA Asia / Latin America 0.51 0.36 0.13 Q2'10 Revenue Reduced general instrument and chest drainage sales Somewhat offset by increased ligation sales Minimally invasive surgical techniques Technology / product advances Emerging markets Instruments Ligation Closure/Che
Slide 12: Cardiac Care
12 Cardiac Care North America EMEA Asia / Latin America 0.28 0.42 0.3 Q2'10 Revenue Increased sales of pumps and catheters in Asian markets Emerging markets Technology innovation Aging population Pumps Catheters Other 0.32 0.66 0.02 End Market Growth Drivers Sales = $18.8 million, up 1% constant cur
Slide 13: OEM
13 OEM Q2'10 Revenue Strength of specialty product sales continue Somewhat offset by weakness of orthopedic product sales Technology innovation Speed to market Demographics Increased regulatory scrutiny on suppliers Specialty Products Orthopedic Products 0.75 0.25 North America EMEA 0.85 0.15 End Ma
Slide 14: Aerospace
14 Aerospace Q2'10 Revenue OEM wide-body sales up due to increased shipments of cargo loading systems to Boeing & Airbus Increase in cargo systems for aftermarket conversions Improved actuator and spare sales Narrow-body cargo loading system unit volume down Container sales up due to slightly improv
Slide 15: Commercial
15 Commercial Q2'10 Revenue Sales = $55.3 million, up 25% constant currency 1 Sales of marine products to OEM manufacturers doubles Aftermarket revenue up 22% Sales of modern burner unit to U.S. military down Global economy Marine 1 End Market Growth Drivers 1 = excludes Rigging Products & Services
Slide 16: R&D / Market Review
R&D / MARKET REVIEW. Teleflex:
Slide 17: New Product Introduction / Market Update
17 PICC Wand Safety Introducer Limited market release at end of second quarter; full market release scheduled for 2H'10 Gibeck Humid-Flo Passive Humidification kit launched in second quarter Anti-microbial PICC - expected to launch in 2H'10 Crystal Clear Plus Trach and TrachFlex Plus - expected to l
Slide 18: Financial Review
FINANCIAL REVIEW Teleflex:
Slide 19: Second Quarter Income Statement from Continuing Operations
19 Second Quarter Income Statement from Continuing Operations Amounts in Millions, except per share
Slide 20: Second Quarter EPS Reconciliation from Continuing Operations
20 Second Quarter EPS Reconciliation from Continuing Operations
Slide 21: Year-to-Date Income Statement from Continuing Operations
21 Year-to-Date Income Statement from Continuing Operations Amounts in Millions, except per share
Slide 22: Year-to-Date EPS Reconciliation from Continuing Operations
22 Year-to-Date EPS Reconciliation from Continuing Operations
Slide 23: Year-to-Date Cash Flow Summary
23 Year-to-Date Cash Flow Summary ($ in Millions)
Slide 24: 2010 Outlook
2010 Outlook Total Revenue ‘Total Company Gross Margins ‘Total Company RAD “Total Company Operating Margins tect Tax Rate Austad ES rom Contig Operations ‘Amertzaton Expense por share Ajusted Cash ES ‘ash Fw from ontnuing Operaton! captal Expenses eprecaton Expense ‘Amortzaton Expense ‘Medal Constan
Slide 25: Summary
25 SUMMARY
Slide 26: Longer-term Growth and Profitability Objectives
26 Longer-term Growth and Profitability Objectives Within the next five years, the Company is targeting the achievement of the following objectives: Consolidated organic revenue growth of approximately 5% Consolidated gross margins of approximately 55% Consolidated research and development expense o
Slide 27: Question & Answer
IESTION & ANSWER Teleflex:
Slide 28: Appendices
APPENDICES Teleflex:
Slide 29: Appendix A - Medical Segment Review
29 Appendix A - Medical Segment Review
Slide 30: Appendix B - Aerospace Segment Review
30 Appendix B - Aerospace Segment Review
Slide 31: Appendix C - Commercial Segment Review
31 Appendix C - Commercial Segment Review
Slide 32: Appendix D - Reconciliation of Medical Operating Profit and Margins
32 Appendix D - Reconciliation of Medical Operating Profit and Margins
Slide 33: Appendix E - Reconciliation of Teleflex Gross Profit and Margins
33 Appendix E - Reconciliation of Teleflex Gross Profit and Margins
Slide 34: Appendix F - Reconciliation of Teleflex Selling and Administrative Expenses
34 Appendix F - Reconciliation of Teleflex Selling and Administrative Expenses
Slide 35: Appendix G - Reconciliation of Teleflex Operating Expenses
35 Appendix G - Reconciliation of Teleflex Operating Expenses
Slide 36: Appendix H - Special Charge Income Statement Classification Summary
36 Appendix H - Special Charge Income Statement Classification Summary
Slide 37: Appendix I - Reconciliation of Teleflex Cash Flow from Continuing Operations
37 Appendix I - Reconciliation of Teleflex Cash Flow from Continuing Operations
Slide 38: Appendix J - Quarter-to-Date Reconciliation of Teleflex Cash EPS Excluding Special Charges
38 Appendix J - Quarter-to-Date Reconciliation of Teleflex Cash EPS Excluding Special Charges
Slide 39: Appendix K - Year-to-Date Reconciliation of Teleflex Cash EPS Excluding Special Charges
39 Appendix K - Year-to-Date Reconciliation of Teleflex Cash EPS Excluding Special Charges
Slide 40: Appendix L - Quarter and Year-to-Date Reconciliation of Medical Constant Currency Revenue Growth
40 Appendix L - Quarter and Year-to-Date Reconciliation of Medical Constant Currency Revenue Growth